waylivra
akcea therapeutics ireland limited - volanesorsen de sodiu - hyperlipoproteinemia tip i - alte lipide modificarea agenți - waylivra este indicat ca adjuvant la dietă la pacienții adulți cu confirmat genetic familial chylomicronemia sindromul (fcs) și cu risc crescut de pancreatită, în care răspunsul la dietă și scăderea trigliceridelor terapie a fost inadecvat.
travatan
novartis europharm limited - travoprostului, - glaucoma, open-angle; ocular hypertension - oftalmologice - scăderea presiunii intraoculare ridicate la pacienții adulți cu hipertensiune oculară sau glaucom cu unghi deschis (vezi secțiunea 5. scăderea presiunii intraoculare crescute la pacienții copii și adolescenți cu vârste cuprinse între 2 luni și < 18 ani, cu hipertensiune oculară sau glaucom pediatric (a se vedea secțiunea 5.
trio thriple therapy package 500 mg + 30 mg + 1000 mg comprimate filmate; capsule; comprimate
deva holding a s - clarithromycinum + lansoprazolum + kalii - comprimate filmate; capsule; comprimate - 500 mg + 30 mg + 1000 mg
prosta urgenin uno capsule moi 320 mg
madaus gmbh - serenoa repens - capsule moi - 320 mg
halopril forte comprimate 5 mg
zdorovie narodu srl, if din harkov - aciclovirum - comprimate - 5 mg
sutent
pfizer limited - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - agenți antineoplazici - gastrointestinal stromal tumour (gist)sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib mesilate treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sutent is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sutent is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults. experience with sutent as first-line treatment is limited (see section 5.
sunitinib accord
accord healthcare s.l.u. - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - agenți antineoplazici - gastrointestinal stromal tumour (gist)sunitinib accord is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sunitinib accord is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sunitinib accord is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pnet) with disease progression in adults.
sunitinib zentiva 12,5 mg
remedica ltd - cipru - sunitinibum - caps. - 12,5mg - inhibitori de protein-kinaza alti inhibitori de protein kinaza
sunitinib zentiva 25 mg
remedica ltd - cipru - sunitinibum - caps. - 25mg - inhibitori de protein-kinaza alti inhibitori de protein kinaza
sunitinib zentiva 37,5 mg
remedica ltd - cipru - sunitinibum - caps. - 37,5mg - inhibitori de protein-kinaza alti inhibitori de protein kinaza